The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.
https://www.pharmalive.com/wp-content/uploads/2023/04/chest-x-ray.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-05-25 10:23:112023-05-25 10:24:05Mirati’s Sitravatinib fails in Phase III lung cancer trial, nixes development
